Aptevo Therapeutics Inc. (APVO) vs PharmaCyte Biotech, Inc. (PMCB)
A side-by-side comparison of Aptevo Therapeutics Inc. and PharmaCyte Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APVO
Aptevo Therapeutics Inc.
$1.80HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PMCB
PharmaCyte Biotech, Inc.
$0.42HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — APVO vs PMCB
growth of $100 · dividends reinvested · last 10yAPVO -100.0% (-80.3%/yr)PMCB -99.3% (-39.0%/yr)PMCB compounded faster over this window
Log scale — wide-divergence pair
APVO PMCB
APVO vs PMCB: by the numbers
- •PMCB is the larger company ($5M vs $4M market cap).
Metrics side by side
Valuation
| Metric | APVO | PMCB |
|---|---|---|
| P/B ratio | 0.65 | 0.16 |
Profitability
| Metric | APVO | PMCB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -437.15% | -54.15% |
| ROIC | -288.14% | -19.51% |
Growth (annualized)
| Metric | APVO | PMCB |
|---|---|---|
| Total return CAGR (5Y) | -95.30% | -33.59% |
Frequently asked
- How have APVO and PMCB total returns compared?
- Over the past 10 years, APVO delivered -80.35% and PMCB delivered -39.91% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.